Education
About Us
Working with TipRanks
Follow Us
Neuroscientific Biopharmaceuticals Ltd. (AU:NSB)
ASX:NSB
NSB Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.26
Previous CloseN/A
Volume70.60K
Average Volume (3M)306.60K
Market Cap
AU$38.25M
Enterprise ValueAU$30.98M
Total Cash (Recent Filing)AU$7.27M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Mar 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding332,575,700
10 Day Avg. Volume291,172
30 Day Avg. Volume306,603
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.76
Price to Sales (P/S)0.00
P/FCF Ratio-13.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-reported debt position provides durable solvency and low fixed-cost obligations, reducing bankruptcy risk and interest expense. This structural strength preserves optionality to pursue R&D, licensing or strategic partnerships without immediate debt servicing constraints.
Positive Equity BufferPositive equity and equity-funded assets give a capital buffer against operational shortfalls, supporting continued development spending. A stronger balance sheet footing improves credibility with partners and investors, facilitating fundraising or collaborations when needed.
Focused Neuroscience R&DA clear strategic focus on neuroscience creates lasting differentiation in a high-barrier, specialty segment with persistent unmet medical needs. Success in this niche can generate durable licensing, partnership or orphan-drug advantages tied to long product lifecycles and intellectual property.
Bears Say
Revenue Collapse And VolatilityA complete revenue collapse and historical volatility materially impair the company's ability to self-fund operations and signal weak commercial traction. Over the medium term this raises dependency on external financing and increases execution risk for sustaining R&D programs.
Persistent Operating LossesRecurring operating losses indicate the business remains in heavy investment mode with no consistent path to profitability yet. This structural deficit erodes returns on equity, limits reinvestment capacity and heightens reliance on dilution or partner funding to continue development.
Ongoing Cash Burn And Weak Cash GenerationSustained negative operating and free cash flow points to chronic cash burn typical of early-stage biotech. Over 2–6 months this necessitates financing actions, increases dilution risk, and pressures management to secure partners or capital to avoid program delays or asset disposals.
Neuroscientific Biopharmaceuticals Ltd. News
NSB FAQ
What was Neuroscientific Biopharmaceuticals Ltd.’s price range in the past 12 months?
Neuroscientific Biopharmaceuticals Ltd. lowest share price was AU$0.03 and its highest was AU$0.26 in the past 12 months.
What is Neuroscientific Biopharmaceuticals Ltd.’s market cap?
Neuroscientific Biopharmaceuticals Ltd.’s market cap is AU$38.25M.
When is Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date?
Neuroscientific Biopharmaceuticals Ltd.’s upcoming earnings report date is Mar 04, 2026 which is in 9 days.
How were Neuroscientific Biopharmaceuticals Ltd.’s earnings last quarter?
Neuroscientific Biopharmaceuticals Ltd. released its earnings results on Aug 28, 2025. The company reported -AU$0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.01.
Is Neuroscientific Biopharmaceuticals Ltd. overvalued?
According to Wall Street analysts Neuroscientific Biopharmaceuticals Ltd.’s price is currently Overvalued.
Does Neuroscientific Biopharmaceuticals Ltd. pay dividends?
Neuroscientific Biopharmaceuticals Ltd. does not currently pay dividends.
What is Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate?
Neuroscientific Biopharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neuroscientific Biopharmaceuticals Ltd. have?
Neuroscientific Biopharmaceuticals Ltd. has 332,575,700 shares outstanding.
What happened to Neuroscientific Biopharmaceuticals Ltd.’s price movement after its last earnings report?
Neuroscientific Biopharmaceuticals Ltd. reported an EPS of -AU$0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Neuroscientific Biopharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:NSB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neuroscientific Biopharmaceuticals Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
265.85%
12-Months-Change
Fundamentals
Return on Equity
-16.65%
Trailing 12-Months
Asset Growth
212.05%
Trailing 12-Months
Company Description
Neuroscientific Biopharmaceuticals Ltd.
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was incorporated in 2002 and is based in Cottesloe, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Starpharma Holdings Limited
―
Island Pharmaceuticals Ltd
―
AnteoTech Ltd
―
Options Prices
Currently, No data available
---